Effects of Bisoprolol and Atenolol on Sympathetic Nervous Activity and Central Aortic Pressure in Patients With Essential Hypertension

A Randomized Controlled Study: Effects of Bisoprolol and Atenolol on Sympathetic Nervous Activity and Central Aortic Pressure in Patients With Essential Hypertension

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01762436

Enrollment

109

Registered

2013-01-07

Start date

2010-11-30

Completion date

2012-02-29

Last updated

2013-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Untreated Essential Hypertension

Brief summary

β-blockers (BBs) with different pharmacological properties may have heterogeneous effects on sympathetic nervous activity (SNA) and central aortic pressure (CAP), which are independent cardiovascular factors for hypertension. Hence, we analyzed the effects of bisoprolol and atenolol on SNA and CAP in hypertensive patients.

Interventions

DRUGbisoprolol

DRUGatenolol

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

25 Years to 65 Years

Healthy volunteers

Inclusion criteria

* 25\ 65 years old * untreated essential hypertension * SBP 140-160mmHg & DBP 90-100mmHg * Sinus rhythm * Resting heart rate \>70bpm * Can give written informed consent

Exclusion criteria

* Atrial Fibrillation (AF)/ Sick Sinus Syndrome (SSS)/ atrioventricular block 2-3 grade(AVBⅡ-Ⅲ) without pacemaker * Bradyarrhythmia/ hypotensive * Unstable Angina Pectoris (UAP)/AMI/ HF (NYHA class III - IV) * Uncontrolled diabetes mellitus (DM) * Bronchial asthma * Gastro-intestinal ulcer or skin ulcer * Liver dysfunction/ renal impairment * Treated with CCB (Calcium antagonists) ( except amlodipine) or other beta blocker. * Glaucoma * Known allergic/ intolerance to beta blocker * Pregnant or lactating women * Participation in another clinical study within the last 3 months * Legal incapacity or limited legal capacity

Design outcomes

Primary

Measure	Time frame	Description
baroreflex sensitivity	4~8 weeks	After 2-week maintenance treatment when the RHR was ≤65 bpm or at 8-week final visit
central aortic pressure	4~8 weeks	After 2-week maintenance treatment when the RHR was ≤65 bpm or at 8-week final visit

Secondary

Measure	Time frame	Description
Number of Participants with Adverse Events as a Measure of Safety and Tolerability	4-8 weeks	After 2-week maintenance treatment when the RHR was ≤65 bpm or at 8-week final visit
heart rate variability	4~8 weeks	After 2-week maintenance treatment when the RHR was ≤65 bpm or at 8-week final visit
peripheral blood pressure	4-8 weeks	After 2-week maintenance treatment when the RHR was ≤65 bpm or at 8-week final visit

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 10, 2026